Fresenius Kabi introduces generic Emend

Fresenius Kabi is offering fosaprepitant for injection in a dosage strength of 150 mg per vial.

The product is a generic of Merck’s Emend. It provides clinicians with a treatment alternative with a 24-month shelf life, the company said.

“Fresenius Kabi is pleased to continue the expansion of one of the most comprehensive generic oncology portfolios in the United States by offering fosaprepitant for injection,” said John Ducker,  Fresenius Kabi USA president and CEO. “We are proud to continue to develop important medicines that are safe, efficacious and affordable.”

Fosaprepitant for injection is a substance P/neurokinin-1 receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy  including high-dose cisplatin; and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.